CTOs on the Move

biozeen

www.biozeen.com

 
biozeen is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.biozeen.com
  • 999 Postal Rd Ste 100
    Allentown, PA USA 18109
  • Phone: 610.703.0828

Executives

Name Title Contact Details

Similar Companies

PrecisionMed

PrecisionMed is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coastal Pharma Group

Coastal Pharma Group is a Oxnard, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revance

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.

Tevogen

Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company`s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio`s foundational vision is a healthier world through equitable access to lifesaving innovations.

Apellis

We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.